Skip to content

Dose-Effect Relationship of Chitosan and Danshen Combined Injection for Fallopian Tube Recanalization

Interventional radiology

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005815
Enrollment
Unknown
Registered
2022-04-05
Start date
2022-04-10
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fallopian tube obstructive infertility

Interventions

D: Combined Chitosan and danshen injections(1 ml chitosan and 10 ml danshen [1:10])
C:Combined Chitosan and danshen injections(2 ml chitosan and 10 ml danshen [1:5])
B:Combined Chitosan and danshen injections(2 ml chitosan and 4 ml danshen [1:2])

Sponsors

Guangzhou panyu central hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
14 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) females of childbearing age (between 22 and 45 years), and (2) a Fallopian tube isthmus or interstitial obstruction diagnosed without adhesions of the fimbriated tubal extremity, determined on laparoscopic examination or salpingography.

Exclusion criteria

Exclusion criteria: (1) pelvic infection, congenital physiological defects or malformations, infertility caused by genetic factors, endocrine factors (follicle-stimulating hormone [FSH] or luteinizing hormone [LH] or other hormones) or immune factors, (2) endometriosis, uterine myoma, uterine hypoplasia, tubal ligation, or pelvic tuberculosis, (3) male partners were diagnosed with reproductive dysfunction.(4)Allergic to the drugs used(5)not prescribed medication treatment or incomplete information.

Design outcomes

Primary

MeasureTime frame
Tubal patency rates;Pregnancy rates;

Countries

China

Contacts

Public ContactChen Huang
05yxhc@163.com13427521943

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026